Truist Securities Starts Arcutis Biotherapeutics Inc. (ARQT) at Buy
- Wall Street falls with Amazon; S&P 500 posts sixth straight month of gains
- Amazon (AMZN) Plunges After Missing Sales and Guidance Expectations, Analysts Slash PTs to Reflect Weaker Guidance
- Pinterest (PINS) Tops Profit and Sales Views, But Shares Plunges Over 20% on a Big Monthly User Miss to Prompt Two Downgrades
- 'I'm CEO.' New Book Outlines Merger Conversations Between Elon Musk and Tim Cook
- Bullard: Fed should taper this fall, go "fairly rapidly" to end early 2022
Truist Securities initiates coverage on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) with a Buy rating and a price target of $38.00.
Shares of Arcutis Biotherapeutics Inc. closed at $24.38 yesterday.
You May Also Be Interested In
- Tigress Financial Partners Starts Royalty Pharma (RPRX) at Buy
- CICC Starts XPeng (XPEV) at Outperform
- Keefe, Bruyette & Woods Reinstates OceanFirst Financial (OCFC) at Outperform
Create E-mail Alert Related CategoriesNew Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!